Alaunos Therapeutics, Inc. Form SCHEDULE 13D/A — Oct 15, 2026
WaterMill Asset Management Corp. and Robert W. Postma amended their Schedule 13D on Alaunos Therapeutics, each reporting beneficial ownership of 9.99% of the common stock, based on 3,440,670 shares outstanding as of October 13, 2026 plus preferred conversion shares, dividends, and options. The amendment discloses that, in connection with the October 13, 2026 Merger Agreement between Alaunos and Velaris Therapeutics, the reporting persons signed a Share Repurchase and Voting Agreement committing to convert and vote their Series A-1 and A-2 Preferred Stock in favor of the merger proposals.
Key figures
- Postma percent
- 9.99%
- Watermill percent
- 9.99%
- Lockup period days
- 180
- Postma shares owned
- 514691
- Watermill shares owned
- 434229
- Shares outstanding base
- 3440670
- Preferred repurchase value
- $1.6 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.